FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4231450319> ?p ?o ?g. }

• W4231450319 endingPage "361" @default.
• W4231450319 startingPage "360" @default.
• W4231450319 abstract "CSF470 therapeutic vaccine is a mixture of four lethally irradiated melanoma cell lines, administered with BCG and GM-CSF, which is being tested in a Phase II/III clinical trial in stage II/III melanoma patients. Currently, irradiated cells that comprise CSF470 vaccine are frozen using dimethyl sulfoxide (Me2SO) as a cryoprotectant and stored in liquid nitrogen (LN2) until its use. Prior to inoculation, each dose must be thawed under sterile conditions, washed to remove Me2SO and finally resuspended until clinical i.d. administration. In order to facilitate CSF470 pharmaceutical production and distribution we need to develop a methodology that allows the preservation of CSF470 in a freeze-dried formulation, avoiding storage in LN2 while keeping its biological and immunogenic properties. To achieve freeze-drying of eukaryotic nucleated cells they should be frozen in the absence of the currently used cryoprotectant Me2SO, this being the critical step. We tested diverse freezing conditions, employing cryoprotectants suitable to be used as excipients in the final product. Since the freeze and thaw process represent a stress for the cells, we also studied hsp 27, 70 and 90 pattern of expression in the four cell lines that comprise the vaccine. We investigated trehalose (TRE) as cell cryoprotectant, both before and after gamma irradiation. We also analyzed TRE uptake by melanoma cells and investigated the Fluid-Phase endocytosis kinetics, employing the fluorescent dye Lucifer Yellow (LYCH). We assayed different compositions of freezing media with TRE and human serum albumin (HSA). We compared samples frozen with TRE and control Me2SO, evaluating cellular integrity (trypan blue exclusion), persistence of vaccine antigens (MART-1, gp100, GD2, GD3 and HLA-A0201, FACS), proliferative capacity (MTT assay) and in case of irradiated cells, the proportion of apoptotic/necrotic cells, by Annexin-V/IP staining. TRE uptake was measured using the anthrone-sulfuric assay. Cells incubated with 0.2 M TRE after 5 h of fluid-phase endocytosis at 37 °C reached an intracellular TRE concentration that varied between 100 and 170 mM for each cell line. Optimal freezing conditions were 0.2 M TRE and 30 mg/ml HSA at − 80 °C. After freezing and subsequent thawing, the number of recovered cells, cellular integrity as well as the presence of specific antigens obtained for CSF470 frozen in TRE were not statistically different to the Me2SO control condition. Furthermore, the apoptosis/necrosis profile after gamma irradiation was similar in both cases. The non-irradiated melanoma cell lines also showed comparable proliferative capacity after both cryoprotection procedures. However, some differences were observed in the separated cell lines in terms of growth kinetics after cryopreservation. Differences in the hsps expression pattern, as detected by Western blot, were found between cell lines, suggesting a possible role for these proteins in their freezing performance. Using the TRE-freezing medium we are able to cryopreserve CSF470 vaccine in the absence of Me2SO at − 80 °C, and under these conditions we could start the vaccine freeze-drying assays." @default.
• W4231450319 created "2022-05-12" @default.
• W4231450319 creator A5003513885 @default.
• W4231450319 creator A5003790809 @default.
• W4231450319 creator A5004184657 @default.
• W4231450319 creator A5011043880 @default.
• W4231450319 creator A5013255290 @default.
• W4231450319 creator A5019322442 @default.
• W4231450319 creator A5022947421 @default.
• W4231450319 creator A5029496571 @default.
• W4231450319 creator A5031899574 @default.
• W4231450319 creator A5070170019 @default.
• W4231450319 date "2012-12-01" @default.
• W4231450319 modified "2023-10-17" @default.
• W4231450319 title "66. Development of a novel methodology for cryopreservation of melanoma cells applied to the CSF470 therapeutic vaccine" @default.
• W4231450319 doi "https://doi.org/10.1016/j.cryobiol.2012.07.067" @default.
• W4231450319 hasPublicationYear "2012" @default.
• W4231450319 type Work @default.
• W4231450319 citedByCount "1" @default.
• W4231450319 countsByYear W42314503192013 @default.
• W4231450319 crossrefType "journal-article" @default.
• W4231450319 hasAuthorship W4231450319A5003513885 @default.
• W4231450319 hasAuthorship W4231450319A5003790809 @default.
• W4231450319 hasAuthorship W4231450319A5004184657 @default.
• W4231450319 hasAuthorship W4231450319A5011043880 @default.
• W4231450319 hasAuthorship W4231450319A5013255290 @default.
• W4231450319 hasAuthorship W4231450319A5019322442 @default.
• W4231450319 hasAuthorship W4231450319A5022947421 @default.
• W4231450319 hasAuthorship W4231450319A5029496571 @default.
• W4231450319 hasAuthorship W4231450319A5031899574 @default.
• W4231450319 hasAuthorship W4231450319A5070170019 @default.
• W4231450319 hasConcept C108939769 @default.
• W4231450319 hasConcept C1491633281 @default.
• W4231450319 hasConcept C153911025 @default.
• W4231450319 hasConcept C178790620 @default.
• W4231450319 hasConcept C179933525 @default.
• W4231450319 hasConcept C185592680 @default.
• W4231450319 hasConcept C196843134 @default.
• W4231450319 hasConcept C2778452553 @default.
• W4231450319 hasConcept C2778452849 @default.
• W4231450319 hasConcept C43617362 @default.
• W4231450319 hasConcept C53227056 @default.
• W4231450319 hasConcept C55493867 @default.
• W4231450319 hasConcept C68528507 @default.
• W4231450319 hasConcept C84199377 @default.
• W4231450319 hasConcept C86803240 @default.
• W4231450319 hasConcept C95444343 @default.
• W4231450319 hasConceptScore W4231450319C108939769 @default.
• W4231450319 hasConceptScore W4231450319C1491633281 @default.
• W4231450319 hasConceptScore W4231450319C153911025 @default.
• W4231450319 hasConceptScore W4231450319C178790620 @default.
• W4231450319 hasConceptScore W4231450319C179933525 @default.
• W4231450319 hasConceptScore W4231450319C185592680 @default.
• W4231450319 hasConceptScore W4231450319C196843134 @default.
• W4231450319 hasConceptScore W4231450319C2778452553 @default.
• W4231450319 hasConceptScore W4231450319C2778452849 @default.
• W4231450319 hasConceptScore W4231450319C43617362 @default.
• W4231450319 hasConceptScore W4231450319C53227056 @default.
• W4231450319 hasConceptScore W4231450319C55493867 @default.
• W4231450319 hasConceptScore W4231450319C68528507 @default.
• W4231450319 hasConceptScore W4231450319C84199377 @default.
• W4231450319 hasConceptScore W4231450319C86803240 @default.
• W4231450319 hasConceptScore W4231450319C95444343 @default.
• W4231450319 hasIssue "3" @default.
• W4231450319 hasLocation W42314503191 @default.
• W4231450319 hasOpenAccess W4231450319 @default.
• W4231450319 hasPrimaryLocation W42314503191 @default.
• W4231450319 hasRelatedWork W2095372620 @default.
• W4231450319 hasRelatedWork W2113973240 @default.
• W4231450319 hasRelatedWork W2356502537 @default.
• W4231450319 hasRelatedWork W2372662679 @default.
• W4231450319 hasRelatedWork W2378278214 @default.
• W4231450319 hasRelatedWork W2531281251 @default.
• W4231450319 hasRelatedWork W2993518625 @default.
• W4231450319 hasRelatedWork W3033787659 @default.
• W4231450319 hasRelatedWork W3084094438 @default.
• W4231450319 hasRelatedWork W3144086378 @default.
• W4231450319 hasVolume "65" @default.
• W4231450319 isParatext "false" @default.
• W4231450319 isRetracted "false" @default.
• W4231450319 workType "article" @default.